Free Trial
NASDAQ:ELVN

Enliven Therapeutics (ELVN) Stock Price, News & Analysis

$21.47
-0.37 (-1.69%)
(As of 06/25/2024 ET)
Today's Range
$21.31
$22.39
50-Day Range
$16.78
$24.70
52-Week Range
$9.80
$26.00
Volume
284,215 shs
Average Volume
256,309 shs
Market Capitalization
$1.01 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$33.00

Enliven Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.33 Rating Score
Upside/​Downside
53.7% Upside
$33.00 Price Target
Short Interest
Bearish
20.28% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Selling Shares
$28.66 M Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($2.26) to ($2.74) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.47 out of 5 stars

Medical Sector

646th out of 890 stocks

Pharmaceutical Preparations Industry

306th out of 427 stocks

ELVN stock logo

About Enliven Therapeutics Stock (NASDAQ:ELVN)

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.

ELVN Stock Price History

ELVN Stock News Headlines

Did Jeff Bezos Just Make the AI Apocalypse Worse?
For the last 18 months, AI has dominated the news cycle unlike anything we've seen in years... And although many have praised the upside, many tech experts, from Elon Musk to Bill Gates, have warned of the catastrophic consequences AI represents. What 99% of people don't realize is that there's an even bigger threat on the horizon.
Did Jeff Bezos Just Make the AI Apocalypse Worse?
For the last 18 months, AI has dominated the news cycle unlike anything we've seen in years... And although many have praised the upside, many tech experts, from Elon Musk to Bill Gates, have warned of the catastrophic consequences AI represents. What 99% of people don't realize is that there's an even bigger threat on the horizon.
See More Headlines
Receive ELVN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Enliven Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/14/2024
Today
6/25/2024
Next Earnings (Estimated)
8/08/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ELVN
Fax
N/A
Employees
46
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$33.00
High Stock Price Target
$34.00
Low Stock Price Target
$32.00
Potential Upside/Downside
+51.1%
Consensus Rating
Buy
Rating Score (0-4)
3.33
Research Coverage
3 Analysts

Profitability

Net Income
$-71,580,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$5.97 per share

Miscellaneous

Free Float
33,302,000
Market Cap
$1.03 billion
Optionable
Optionable
Beta
1.11
Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

  • Mr. Samuel S. Kintz M.B.A. (Age 38)
    Co-Founder, CEO, Secretary & Director
    Comp: $597k
  • Dr. Helen Louise Collins M.D. (Age 61)
    Chief Medical Officer
    Comp: $558k
  • Dr. Joseph P. Lyssikatos Ph.D. (Age 59)
    Co-Founder, Chief Scientific Officer & Directors
  • Dr. Galya D. Blachman Esq. (Age 47)
    Ph.D., Chief Legal Officer & Head of Business Development

ELVN Stock Analysis - Frequently Asked Questions

Should I buy or sell Enliven Therapeutics stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Enliven Therapeutics in the last twelve months. There are currently 2 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" ELVN shares.
View ELVN analyst ratings
or view top-rated stocks.

What is Enliven Therapeutics' stock price target for 2024?

3 brokerages have issued twelve-month target prices for Enliven Therapeutics' shares. Their ELVN share price targets range from $32.00 to $34.00. On average, they predict the company's share price to reach $33.00 in the next year. This suggests a possible upside of 53.7% from the stock's current price.
View analysts price targets for ELVN
or view top-rated stocks among Wall Street analysts.

How have ELVN shares performed in 2024?

Enliven Therapeutics' stock was trading at $13.84 at the beginning of 2024. Since then, ELVN shares have increased by 55.1% and is now trading at $21.47.
View the best growth stocks for 2024 here
.

When is Enliven Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 8th 2024.
View our ELVN earnings forecast
.

How were Enliven Therapeutics' earnings last quarter?

Enliven Therapeutics, Inc. (NASDAQ:ELVN) posted its quarterly earnings data on Tuesday, May, 14th. The company reported ($0.54) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.58) by $0.04.

What ETFs hold Enliven Therapeutics' stock?

ETFs with the largest weight of Enliven Therapeutics (NASDAQ:ELVN) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR).Loncar China Biopharma ETF (CHNA).

Who are Enliven Therapeutics' major shareholders?

Enliven Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (2.52%), Janus Henderson Group PLC (1.52%), Baker BROS. Advisors LP (0.24%), Blackstone Inc. (0.05%), California State Teachers Retirement System (0.04%) and EntryPoint Capital LLC (0.02%). Insiders that own company stock include 5Am Partners Vi, Llc, Anish Patel, Benjamin Hohl, Joseph P Lyssikatos, Rahul D Ballal, Richard A Heyman, Rishi Gupta and Samuel Kintz.
View institutional ownership trends
.

How do I buy shares of Enliven Therapeutics?

Shares of ELVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ELVN) was last updated on 6/25/2024 by MarketBeat.com Staff

From Our Partners